Literature DB >> 11257406

Immune responses to ISCOM formulations in animal and primate models.

A Sjölander1, D Drane, E Maraskovsky, J P Scheerlinck, A Suhrbier, J Tennent, M Pearse.   

Abstract

ISCOMs are typically 40 nm cage-like structures comprising antigen, saponin, cholesterol and phospholipid. ISCOMs have been shown to induce antibody responses and activate T helper cells and cytolytic T lymphocytes in a number of animal species, including non-human primates. Recent clinical studies have demonstrated that ISCOMs are also able to induce antibody and cellular immune responses in humans. This review describes the current understanding of the ability of ISCOMs to induce immune responses and the mechanisms underlying this property. Recent progress in the characterisation and manufacture of ISCOMs will also be discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257406     DOI: 10.1016/s0264-410x(00)00497-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

2.  Reduced MyD88 dependency of ISCOMATRIX™ adjuvant in a DNA prime-protein boost HIV vaccine.

Authors:  Rachel Buglione-Corbett; Kimberly Pouliot; Robyn Marty-Roix; Wei Li; Kim West; Shixia Wang; Adriana Baz Morelli; Egil Lien; Shan Lu
Journal:  Hum Vaccin Immunother       Date:  2014-02-10       Impact factor: 3.452

Review 3.  Adjuvant effects of saponins on animal immune responses.

Authors:  Zahid Iqbal Rajput; Song-hua Hu; Chen-wen Xiao; Abdullah G Arijo
Journal:  J Zhejiang Univ Sci B       Date:  2007-03       Impact factor: 3.066

4.  How well can a T-cell epitope replace its parent carrier protein? A dose-response study.

Authors:  James S Cavenaugh; Hsu-Kun Wang; Cory Hansen; Richard S Smith; James N Herron
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

5.  Effect of adjuvants on the humoral immune response to congopain in mice and cattle.

Authors:  John Kateregga; George W Lubega; Erik B Lindblad; Edith Authié; Theresa Helen Taillefer Coetzer; Alain François Vincent Boulangé
Journal:  BMC Vet Res       Date:  2012-05-23       Impact factor: 2.741

6.  Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy.

Authors:  Rachel Buglione-Corbett; Kimberly Pouliot; Robyn Marty-Roix; Kim West; Shixia Wang; Egil Lien; Shan Lu
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

7.  The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice.

Authors:  Ahmad Mehravaran; Mahmoud Reza Jaafari; Seyed Amir Jalali; Ali Khamesipour; Reza Ranjbar; Mansure Hojatizade; Ali Badiee
Journal:  Iran J Basic Med Sci       Date:  2016-02       Impact factor: 2.699

8.  Immunization Against Cutaneous Leishmaniasis by Alginate Microspheres Loaded With Autoclaved Leishmania Major (ALM) and Quillaja Saponins.

Authors:  Mohsen Tafaghodi; Maryam Eskandari; Ali Khamesipour; Mahmoud Reza Jaafari
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

Review 9.  Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.

Authors:  Blaise Corthésy; Gilles Bioley
Journal:  Front Immunol       Date:  2018-03-07       Impact factor: 7.561

10.  Mannosylated mucin-type immunoglobulin fusion proteins enhance antigen-specific antibody and T lymphocyte responses.

Authors:  Gustaf Ahlén; Lena Strindelius; Tomas Johansson; Anki Nilsson; Nathalie Chatzissavidou; Magnus Sjöblom; Ulrika Rova; Jan Holgersson
Journal:  PLoS One       Date:  2012-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.